This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
15 Aug 2013

Clinical Trials of Insulin Therapy Yields Positive Results

Clinical trials of the mealtime insulin therapy AFREZZA, used to treat type 1 and type 2 diabetes, have shown positive results.

AFREZZA, developed by MannKind Corporation, is an inhalation powder that is administered using an inhaler. Patients take the inhaler at the start of a meal and the powder instantly dissolves, quickly delivering insulin to the bloodstream.

In one of AFREZZA's clinical trials, MannKind found that patients with type 1 diabetes experienced a significant decrease in fasting glucose levels and much less hypoglycemia. A trial of AFREZZA among type 2 diabetes sufferers showed postprandial glucose excursions were reduced.

Chief executive officer of MannKind Corporation Alfred Mann said the studies would be used to assess how to amend the drug before presenting it to FDA

According to the World Health Organisation (WHO), 347 million people around the globe suffer from diabetes. In 2004, 3.4 million people died as a result of high fasting blood sugar. Additionally, WHO predicts that diabetes will be the 7th leading cause of death in 2030.
 

Related News